Management of dabigatran-induced bleeding with continuous venovenous hemodialysis

International Journal of Hematology

Volumn 101, Issue 6, 2015, Pages 594-597

  Paul, Suman ^a   Hamouda, Danae ^a   Prashar, Rohini ^a   Mbaso, Chiamaka ^a   Khan, Abdur ^a   Ali, Abdulmonam ^a   Shah, Sarthi ^a   Assaly, Ragheb ^a  

^a UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

Author keywords

aPTT; Atrial fibrillation; Continuous venovenous hemodialysis CVVHD; Dabigatran; International normalized ration INR; Thrombin time TT

Indexed keywords

BICARBONATE; CREATININE; DABIGATRAN; FRESH FROZEN PLASMA; HEMOGLOBIN; HYPERTENSIVE FACTOR; POLYSULFONE; SODIUM CHLORIDE; ANTITHROMBIN;

ACUTE KIDNEY FAILURE; AGED; ANEMIA; ARGON PLASMA COAGULATION; ARTICLE; ATRIAL FIBRILLATION; BLOOD CLOTTING DISORDER; BLOOD FLOW VELOCITY; CASE REPORT; CHRONIC KIDNEY DISEASE; COLONOSCOPY; CONTINUOUS HEMODIALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRYSTALLOID; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMOGLOBIN BLOOD LEVEL; HEMORRHAGIC SHOCK; HUMAN; HYPOTENSION; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; MEAN ARTERIAL PRESSURE; PARTIAL THROMBOPLASTIN TIME; STOMACH EROSION; THROMBIN TIME; THROMBOCYTE TRANSFUSION; URINE VOLUME; BLOOD; BLOOD CLOTTING TEST; BLOOD TRANSFUSION; CHEMICALLY INDUCED; COMPLICATION; DRUG OVERDOSE; HEMODIALYSIS; PROCEDURES;

AGED; ANTITHROMBINS; BLOOD COAGULATION TESTS; BLOOD TRANSFUSION; DABIGATRAN; DRUG OVERDOSE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; RENAL DIALYSIS;

EID: 84930573699     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-015-1739-7     Document Type: Article

References (9)

1. IMS, Vector One®: National (VONA) and Total Patient Tracker (TPT) Database. October 2010 to August 2012, www.fda.org.
2. Redondo S, Martínez M-P, Ramajo M, Navarro-Dorado J, Barez A, Tejerina T. Pharmacological basis and clinical evidence of dabigatran therapy. J Hematol Oncol. 2011;4(1):53.
3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.
4. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116–27.
5. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood. 2012;119(9):2172–4.
6. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49(4):259–68.
7. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573–9.
8. Weinz C, Buetehorn U, Daehler HP, Kohlsdorfer C, Pleiss U, Sandmann S, et al. Pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—in rats and dogs. Xenobiotica. 2005;35(9):891–910.
9. Mueck W, Schwers S, Stampfuss J. Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J. 2013;11(1):10.